05/19/22 7:00 AMNasdaq : OCUP clinical triallow floatOcuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision DisturbancesMet FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial for the Large Unmet Need of Treating Night Vision Disturbances (NVD) in Subjects Experiencing Glare,RHEA-AIneutral
05/13/22 8:00 AMNasdaq : OCUP earningslow floatOcuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate UpdateNyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in First Quarter NDA Filing on Track for Late 2022 for Potential 2023 Approval of Nyxol as Only Dilation Reversal Drop Data Expected in 2H22 fromRHEA-AIneutral
05/11/22 8:00 AMNasdaq : OCUP conferencesclinical triallow floatOcuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment ConferenceOcuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations byRHEA-AIneutral
04/28/22 7:00 AMNasdaq : OCUP clinical triallow floatOcuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of MydriasisNyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials MIRA-4 Results Support Potential Broader Label for Nyxol in RM to Include Pediatrics NDA Filing forRHEA-AIpositive
04/26/22 9:00 AMNasdaq : OCUP low floatOcuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022Ocuphire Pharma, Inc. (Nasdaq: OCUP), aRHEA-AIpositive
04/19/22 8:00 AMNasdaq : OCUP managementconferenceslow floatOcuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and EyeceleratorOcuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmicRHEA-AIpositive
04/06/22 8:00 AMNasdaq : OCUP conferenceslow floatOcuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MAOcuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch,RHEA-AIneutral
03/29/22 7:00 AMNasdaq : OCUP clinical triallow floatOcuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of MydriasisMeets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects (p<0.0001) MIRA-3 Confirms Prior MIRA-2 Phase 3 Registration Trial Showing Substantial Benefit in Accelerating Reversal of Mydriasis (RM) NDA Filing forRHEA-AIneutral
03/24/22 8:00 AMNasdaq : OCUP earningslow floatOcuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate UpdateBuilding Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022: – Nyxol ® MIRA-3 Phase 3 Results Expected End of 1Q 2022 – MIRA-4 Pediatric, and LYNX-1 Phase 3 Results Expected to follow in 2Q 2022 – ZETA-1 Phase 2 DiabeticRHEA-AIpositive
03/16/22 7:30 AMNasdaq : OCUP clinical triallow floatOcuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic RetinopathySuccessful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022 APX3330 as an Oral Therapy Has the Potential to Treat Over 7 Million Diabetic Retinopathy Patients With Limited Treatment Options Rapid Enrollment forRHEA-AIneutral